Syngene acquires first US biologics facility for $36.5 million

Overall investment in the US facility is estimated around US$50 million

Biocon Biologics announces positive results from Phase 3 study of Yesintek biosimilar to Ustekinumab for chronic plaque psoriasis

The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara

Dr. Agarwals Eye Hospital inaugurates its third facility in Mysore

This addition strengthens Dr. Agarwals Eye Hospital's vast network of 28 hospitals across Karnataka and 220+ facilities worldwide

Biocon Biologics and Civica collaborate to expand Insulin Aspart access in US

There are 38.4 million people with diabetes in the United States

Metropolis Healthcare to acquire Agra's Scientific Pathology

Metropolis Clinical Pathology will acquire and operate all laboratories and collection centers of Scientific Pathology in Agra and neighbouring towns through a slump sale transaction

Zydus and Gates Foundation to develop world’s first combination vaccine to offer protection against shigellosis and typhoid

Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine

Philips and Medtronic partner to upskill 300+ clinicians in structural heart imaging in India

Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India

MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies

FDA grants EUA to Aptitude’s Covid/flu multiplex test for OTC use

Biocon Biologics launches Yesintek Biosimilar to Stelara in US

YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis